Sarah Tomassetti
Hematology & Oncology · Torrance, CANPI 1003159427
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,491 of the $12,804 with a category attached, or 74.1%. 30 manufacturers reported payments, led by Novartis at 38.8% of the total. Reporting peaked in 2024 at $7,202 and has fallen 66.0% since, to $2,449 in 2025.
Across 81 payments — averaging $158.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- AstraZeneca$3K
- Taiho Oncology, Inc.$2K
- Rigel Pharmaceuticals, Inc.$1K
- Sanofi$522
- Genentech USA, Inc.$328
- plus $1K from 24 others
Across 131 payments — averaging $22,813 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.8M
- Merck$563K
- Genentech, Inc.$193K
- Seagen Inc.$164K
- Sanofi US Services Inc.$103K
- Rigel Pharmaceuticals, Inc.$96K
- plus $100K from 2 others
What the payments were for
- Consulting fees$9,49174%
- Speaking & faculty fees$1,46311%
- Food & beverage$1,74514%
- Education$1061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 3 | $4,963 |
| AstraZeneca(2 entities) | 7 | $2,681 |
| Taiho Oncology, Inc. | 1 | $1,560 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,463 |
| Sanofi | 3 | $522 |
| Genentech USA, Inc. | 14 | $328 |
| Pfizer | 11 | $170 |
| Lilly USA, LLC | 4 | $150 |
| Incyte Corporation | 4 | $104 |
| Bristol Myers Squibb | 3 | $95 |
| Merck | 4 | $81 |
| E.r. Squibb & Sons, L.L.C. | 6 | $80 |
| GSK | 1 | $67 |
| Amgen | 2 | $62 |
| EMD Serono, Inc. | 1 | $50 |
| Seagen Inc. | 2 | $42 |
| Exelixis Inc. | 1 | $41 |
| Johnson & Johnson | 1 | $40 |
| Blueprint Medicines Corporation | 1 | $36 |
| ADC Therapeutics America, Inc. | 1 | $33 |
| Gilead | 1 | $30 |
| Karyopharm Therapeutics Inc. | 1 | $29 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $28 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| Adaptive Biotechnologies Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,804 in reported general payments places this provider in the 70th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Torrance
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.